DePuy knew about hip implant’s high failure rate three years before it was recalledBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f626 (Published 29 January 2013) Cite this as: BMJ 2013;346:f626
- Deborah Cohen
Post-marketing studies carried out by the US orthopaedic company DePuy showed a high revision rate for its ASR (articular surface replacement) hip implant three years before it was recalled from the global market, newly released internal documents show.
The controversial prosthesis was recalled in August 2010 after “new data” from the National Joint Registry of England and Wales showed that it was failing at a higher rate than competing implants, a “Dear doctor” letter sent out by the company to surgeons said. It stated revision rates of 8-9% at three years.
The ASR comes in two types, one used in a resurfacing technique and the other as part of a total hip replacement called the ASR XL.
However, an unpublished survival analysis conducted in June 2007 from the company’s own database showed …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial